MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?

References

• Word Health Organization. Cancer. ; 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March 20, 2024.
   Google Scholar
• Society AC American Cancer Society. What Is Lung Cancer? Available from: https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed March 20, 2024.
   Google Scholar
• Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8(2):179–184. doi:10.1097/JTO.0b013e3182779d18
   PubMed Web of Science ®Google Scholar
• Bauml JM, Viteri S, Minchom A, et al. FP07.12 underdiagnosis of EGFR exon 20 insertion mutation variants: estimates from ngs-based real-world datasets. J Thorac Oncol. 2021;16(3):S208–S209. doi:10.1016/j.jtho.2021.01.112
   Web of Science ®Google Scholar
• Pennell NA, Neal JW, Chaft JE, et al. SELECT: a Phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer. J Clin Oncol. 2019;37(2):97–104. doi:10.1200/JCO.18.00131
   PubMed Web of Science ®Google Scholar
• Burnett H, Emich H, Carroll C, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. PLoS One. 2021;16(3):e0247620. doi:10.1371/journal.pone.0247620
   PubMed Web of Science ®Google Scholar
• Zhang YL, Yuan J-Q, Wang K-F, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985–78993. doi:10.18632/oncotarget.12587
   PubMedGoogle Scholar
• Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892–2911.
   PubMed Web of Science ®Google Scholar
• Girard N, Bazhenova L, Minchom A, et al. ma04.07 comparative clinical outcomes for patients with NSCLC harboring egfr exon 20 insertion mutations and common EGFR mutations. J Thorac Oncol. 2021;16(3):S145–S146. doi:10.1016/j.jtho.2021.01.228
   Web of Science ®Google Scholar
• Lin JJ, Cardarella S, Lydon CA, et al. Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. J Thorac Oncol. 2016;11(4):556–565. doi:10.1016/j.jtho.2015.12.103
   PubMed Web of Science ®Google Scholar
• Shimamura SS, Shukuya T, Asao T, et al. Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a “tail plateau” in the survival curve of these patients? BMC Cancer. 2022;22(1):323. doi:10.1186/s12885-022-09421-7
   PubMedGoogle Scholar
• US Food & Drug Administration. FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-amivantamab-vmjw-metastatic-non-small-cell-lung-cancer. Accessed March 20, 2024.
   Google Scholar
• Cho BC, Kim D-W, Spira AI, et al. Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a Phase 1 trial. Nat Med. 2023;29(10):2577–2585. doi:10.1038/s41591-023-02554-7
   PubMed Web of Science ®Google Scholar
• Haura EB, Cho BC, Lee JS, et al. JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). J Clin oncol. 2019;37(15_suppl):9009. doi:10.1200/JCO.2019.37.15_suppl.9009
   Web of Science ®Google Scholar
• Ahn M-J, Han J-Y, Kim S-W, et al. Lazertinib, a 3 rd generation EGFR-TKI, in patients with EGFR-TKI resistant NSCLC: updated results of phase I/II Study. J Clin oncol. 2019;37(15_suppl):9037. doi:10.1200/JCO.2019.37.15_suppl.9037
   Google Scholar
• Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase i study. J Clin Oncol. 2021;39(30):3391–3402. doi:10.1200/JCO.21.00662
   PubMed Web of Science ®Google Scholar
• Ahn MJ, Han J-Y, Lee KH, et al. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. Lancet Oncol. 2019;20(12):1681–1690. doi:10.1016/S1470-2045(19)30504-2
   PubMed Web of Science ®Google Scholar
• Dhillon S. Lazertinib: first Approval. Drugs. 2021;81(9):1107–1113. doi:10.1007/s40265-021-01533-x
   PubMed Web of Science ®Google Scholar
• Yun J, Hong MH, Kim S-Y, et al. YH25448, an irreversible egfr-tki with potent intracranial activity in EGFR mutant non-small cell lung cancer. Clin Cancer Res. 2019;25(8):2575–2587. doi:10.1158/1078-0432.CCR-18-2906
   PubMed Web of Science ®Google Scholar
• Sabari JK, Shu CA, Park K, et al. OA04.04 amivantamab in post-platinum EGFR Exon 20 insertion mutant non-small cell lung cancer. J Thorac Oncol. 2021;16(3):S108–S109. doi:10.1016/j.jtho.2021.01.284
   Web of Science ®Google Scholar
• Jänne PA, Yang JC-H, Kim D-W, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689–1699. doi:10.1056/NEJMoa1411817
   PubMed Web of Science ®Google Scholar
• Cho BC, Ahn M-J, Kang JH, et al. Lazertinib Versus Gefitinib as first-line treatment in patients with EGFR -mutated advanced non–small-cell lung cancer: results from LASER301. J Clin Oncol. 2023;41(26):4208–4217. doi:10.1200/JCO.23.00515
   PubMed Web of Science ®Google Scholar
• Cho BC, Lee S-H, Han J-Y, et al. P1.16-01 amivantamab and lazertinib in treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC). J Thorac Oncol. 2022;17(9):S126. doi:10.1016/j.jtho.2022.07.210
   Web of Science ®Google Scholar
• Lee S-H, Cho BC, Han J-Y, et al. Amivantamab and lazertinib in treatment-naïve EGFR- mutated advanced non–small-cell lung cancer (NSCLC): long-term follow-up and ctDNA results from CHRYSALIS. J Clin oncol. 2023;41(16_suppl):9134. doi:10.1200/JCO.2023.41.16_suppl.9134
   Web of Science ®Google Scholar
• Besse B, Baik CS, Marmarelis ME, et al. Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR -mutated NSCLC in the post-osimertinib setting: analysis of tissue IHC and ctDNA NGS. J Clin oncol. 2023;41(16_suppl):9013. doi:10.1200/JCO.2023.41.16_suppl.9013
   Web of Science ®Google Scholar
• Cho BC, Felip E, Spira AI, et al. LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): primary results from MARIPOSA, a Phase III, global, randomized, controlled trial. Ann Oncol. 2023;34:S1306. doi:10.1016/j.annonc.2023.10.062
   Web of Science ®Google Scholar
• Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26. doi:10.1126/scitranslmed.3002003
   PubMed Web of Science ®Google Scholar
• Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFRmutant lung cancers. Clin Cancer Res. 2013;19(8):2240–2247. doi:10.1158/1078-0432.CCR-12-2246
   PubMed Web of Science ®Google Scholar
• Schmid S, Li JJN, Leighl NB. Mechanisms of osimertinib resistance and emerging treatment options. Lung Cancer. 2020;147:123–129. doi:10.1016/j.lungcan.2020.07.014
   PubMed Web of Science ®Google Scholar
• Leonetti A, Sharma S, Minari Ret al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121(9):725–737. doi:10.1038/s41416-019-0573-8
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Cheng Y, Zhou C, et al. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol. 2018;29:740. doi:10.1093/annonc/mdy424.063
   Google Scholar
• Yu HA, Kerr K, Rolfo CD, et al. Detection of MET amplification (MET amp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib. J Clin oncol. 2023;41(16_suppl):9074. doi:10.1200/JCO.2023.41.16_suppl.9074
   Web of Science ®Google Scholar
• Passaro A, Cho BC, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the Phase 3 MARIPOSA-2 study. Ann Oncol. 2023;34:S1307. doi:10.1016/j.annonc.2023.10.063
   Web of Science ®Google Scholar
• Jänne PA, Planchard D, Cheng Y, et al. Osimertinib with/without platinum-based chemotherapy as first-line treatment in patients with EGFRm advanced NSCLC (FLAURA2). In World Conference on Lung Cancer. September 9–12; 2023; Singapore.
   Google Scholar